| Identification | Back Directory | [Name]
CCT 018159 | [CAS]
171009-07-7 | [Synonyms]
CCT 018159
HSP90 Inhibitor, CCT018159 - CAS 171009-07-7 - Calbiochem
4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethyl-1,3-benzenediol
1,3-Benzenediol, 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethyl- | [Molecular Formula]
C20H20N2O4 | [MDL Number]
MFCD00710300 | [MOL File]
171009-07-7.mol | [Molecular Weight]
352.38 |
| Chemical Properties | Back Directory | [Boiling point ]
547.3±50.0 °C(Predicted) | [density ]
1.322±0.06 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | [form ]
White solid | [pka]
8.84±0.48(Predicted) | [color ]
White to off-white | [Water Solubility ]
water: 1.7mg/mL
DMSO: 35mg/mL
ethanol: 35mg/mL |
| Hazard Information | Back Directory | [Uses]
CCT 018159 is a cell-permeable compound that inhibits Hsp90 ATPase. | [Definition]
ChEBI: A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively. | [Biological Activity]
Novel inhibitor of heat shock protein 90 (Hsp90) ATPase activity (IC 50 = 5.7 μ M) that displays selectivity over human Hsp72 and topoisomerase II. Inhibits proliferation of HCT116 human colon tumor cells and produces upregulation of Hsp70 and downregulation of c-Raf and cdk4. More soluble than 17-AAG (17-Demethoxy-17-(2-propenylamino)geldanamycin ) and is independent of NQO1/DT-diaphorase and P-glycoprotein expression. | [in vitro]
cct018159 was identified by high-throughput screening inhibiting human hsp90beta with comparable potency to 17-aag and with similar atp-competitive kinetics. x-ray crystallographic structures of the yeast hsp90 complexed with cct018159 showed binding properties similar to radicicol. the mean cellular gi50 of cct018159 across a panel of human cancer cell lines, including melanoma, was 5.3 μm. unlike 17-aag, the in-vitro antitumor activity of cct018159 was independent of nqo1/dt-diaphorase and p-glycoprotein expression. the signature of hsp90 inhibition, comprising increased expression of hsp72 protein and depletion of erbb2, cdk4, c-raf, and mutant b-raf, was indicated in human cancer cell lines treated with cct018159 [1]. | [in vivo]
in human tumor xenografts including skmel 28 melanoma cells, cct018159 was found to induce the expression of hsp72 as well as erbb2, cdk4 and dc-raf [1]. | [IC 50]
3.2 and 6.6 μm for human hsp90β and yeast hsp90, respectively | [storage]
Store at +4°C | [References]
[1] s. y. sharp, k. boxall, m. rowlands, et al. in vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. cancer research 67(5), 2206-2216 (2007). |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|